Ashvin Shetty, CFA
Ashvin is one of the Founders of Marcellus.
He has more than 10 years of experience in equity research and led the coverage on automobile sector at Ambit Capital.
Ashvin has more than 10 years of experience in equity research. He led the coverage on automobile sector at Ambit Capital from 2010 to 2017. He thereafter worked as a senior analyst for Ambit’s Mid and Small cap PMS funds till November 2018. Prior to joining Ambit, he worked with Execution Noble as an analyst covering consumer and media space. He has also worked with KPMG’s and Deloitte’s statutory audit departments from 2004 to 2007 gaining extensive experience across Indian accounting standards and financial statement analysis.
Qualifications: Ashvin is a BCom graduate from Narsee Monjee College (Mumbai). He is a qualified Chartered Accountant (ICAI India) and Chartered Financial Analyst (CFA Institute, USA).
Articles by team Marcellus
Diversification in a Concentrated Portfolio of Compounders
In an uncertain macroeconomic environment shaped by AI disruption and shifting global geopolitics, the Consistent Compounders Portfolio (CCP) strategy has evolved significantly. While maintaining a concentrated portfolio focused on good-quality businesses, we have diversified our top holdings across uncorrelated sectors such as healthcare, auto components, and export-led manufacturing. This deliberate shift away from our historical […]
READ MORE
Marcellus' Portfolio Updates & Insights - February 2026
marcellus.in From Our CIO’s Desk RBI’s Report Flags Indian Consumer’s Debt Trap For the past year, we have warned that the Indian middle class is financing its lifestyle through a precarious reliance on debt. The RBI’s latest Financial Stability Report (FSR) has now validated these concerns, signalling that the “consumption story” is hitting a wall […]
READ MORE
Drug Discovery is Being Revolutionized & What It Could Mean for Investors
Google DeepMind’s success in using AI to crack protein folding (one of the hardest problems in science) has revolutionized medical research. Research that used to take decades now takes a few years. This makes it likely that the speed of new drug discovery will increase. To gain exposure to this combination of AI & medicine, […]
READ MORE
Also featured in
Demystifying the Security of Clients' Monies in PMS & Mutual Funds
The Global Compounders: AI, Valuations, and the Road Ahead
SMID on the Mend: A Deep Dive into our Little Champs & Rising Giants' Revival